Molecular mechanism of miR-204 regulates proliferation, apoptosis and autophagy of cervical cancer cells by targeting ATF2

References

• Small W Jr, Bacon MA, Bajaj A, et al. Cervical cancer: a global health crisis. Cancer. 2017;123:2404–2412.
   PubMed Web of Science ®Google Scholar
• Song B, Ding C, Chen W, et al. Incidence and mortality of cervical cancer in China, 2013. Chin J Cancer Res. 2017;29:471–476.
   PubMed Web of Science ®Google Scholar
• Crafton SM, Salani R. Beyond chemotherapy: an overview and review of targeted therapy in cervical cancer. Clin Ther. 2016;38:449–458.
   PubMed Web of Science ®Google Scholar
• Gulyaeva LF, Kushlinskiy NE. Regulatory mechanisms of microRNA expression. J Transl Med. 2016;14:143–153.
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203–222.
   PubMed Web of Science ®Google Scholar
• Wang X, Qiu W, Zhang G, et al. MicroRNA-204 targets JAK2 in breast cancer and induces cell apoptosis through the STAT3/BCl-2/survivin pathway. Int J Clin Exp Pathol. 2015;8:5017–5025.
   PubMed Web of Science ®Google Scholar
• Zhang B, Yin Y, Hu Y, et al. MicroRNA-204-5p inhibits gastric cancer cell proliferation by downregulating USP47 and RAB22A. Med Oncol. 2015;32:331–338.
   PubMed Web of Science ®Google Scholar
• Lewis DR, Chen HS, Cockburn MG, et al. Early estimates of SEER cancer incidence, 2014. Cancer. 2017;123:2524–2534.
   PubMed Web of Science ®Google Scholar
• Wang J, Bai Z, Wang Z, et al. Comparison of secular trends in cervical cancer mortality in China and the United States: an age-period-cohort analysis. Int J Environ Res Public Health. 2016;13:1–16.
   Web of Science ®Google Scholar
• Melan K, Janky E, Macni J, et al. Epidemiology and survival of cervical cancer in the French West-Indies: data from the Martinique Cancer Registry (2002–2011). Glob Health Action. 2017;10:1–8.
   Web of Science ®Google Scholar
• Vincerževskienė I, Jasilionis D, Austys D, et al. Education predicts cervical cancer survival: a Lithuanian cohort study. Eur J Public Health. 2017;27:421–424.
   PubMed Web of Science ®Google Scholar
• Lowy DR. HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. J Clin Invest. 2016;126:5–11.
   PubMed Web of Science ®Google Scholar
• Wardak S. Human papillomavirus (HPV) and cervical cancer. Med Dosw Mikrobiol. 2016;68:73–84.
   PubMedGoogle Scholar
• Yang DY, Bracken K. Update on the new 9-valent vaccine for human papillomavirus prevention. Can Fam Physician. 2016;62:399–402.
   PubMed Web of Science ®Google Scholar
• Christopher AF, Kaur RP, Kaur G, et al. MicroRNA therapeutics: discovering novel targets and developing specific therapy. Perspect Clin Res. 2016;7:68–74.
   PubMedGoogle Scholar
• Vishnubalaji R, Hamam R, Yue S, et al. MicroRNA-320 suppresses colorectal cancer by targeting SOX4, FOXM1, and FOXQ1. Oncotarget. 2016;7:35789–35802.
   PubMedGoogle Scholar
• Liu Z, Sun J, Liu B, et al. miRNA-222 promotes liver cancer cell proliferation, migration and invasion and inhibits apoptosis by targeting BBC3. Int J Mol Med. 2018;42:141–148.
   PubMed Web of Science ®Google Scholar
• Wu ZY, Wang SM, Chen ZH, et al. MiR-204 regulates HMGA2 expression and inhibits cell proliferation in human thyroid cancer. Cancer Biomark. 2015;15:535–542.
   PubMed Web of Science ®Google Scholar
• Liu Z, Long J, Du R, et al. miR-204 regulates the EMT by targeting snai1 to suppress the invasion and migration of gastric cancer. Tumor Biol. 2016;37:1–9.
   PubMedGoogle Scholar
• Shu L, Zhang Z, Cai Y. MicroRNA-204 inhibits cell migration and invasion in human cervical cancer by regulating transcription factor 12. Oncol Lett. 2018;15:161–166.
   PubMed Web of Science ®Google Scholar
• Bollmann A, Husser D. ATF2: a transcription factor that elicits oncogenic or tumor suppressor activities. Cell Cycle. 2008;7:2341–2345.
   PubMed Web of Science ®Google Scholar
• Wu DS, Chen C, Wu ZJ, et al. ATF2 predicts poor prognosis and promotes malignant phenotypes in renal cell carcinoma. J Exp Clin Cancer Res. 2016;35:1–11.
   PubMed Web of Science ®Google Scholar
• Song S, Fajol A, Tu X, et al. miR-204 suppresses the development and progression of human glioblastoma by targeting ATF2. Oncotarget. 2016;7:70058–70065.
   PubMedGoogle Scholar